Plasmapheresis and immunoglobulin therapy
スポンサーリンク
概要
- 論文の詳細を見る
Plasmapheresis (PP) and intravenous immunoglobulin (IVIG) are both effective for treatment of crisis and acute exacerbation of myasthenia gravis. The 1st clinical problem is that effect of both treatments usually lasts for only 2-3 weeks. Additional immunosuppressive treatments may be necessary for prevention of the relapse. The 2nd problem is adverse effects and complications associated with each treatment. Hypotension, including shock, thromboembolism, and opportunistic infections are major adverse events of PP. Awareness of these complications and careful practice should be solutions. IVIG complicates less adverse effects than PP. The cost of each treatment, which is expensive particularly in IVIG use, may become the 3rd problem. It should be important to clarify the appropriate number of PP and the dose of IVIG to improve myasthenic crisis.
- 日本神経学会の論文
日本神経学会 | 論文
- 書字動作の神経科学 : 書字運動の計算理論モデルを中心に
- 重症筋無力症に合併した難治性バセドウ眼症の1例
- 神経サルコイドーシスの診断基準案
- 大腸癌とその転移にともなう凝固線溶系の異常により脊髄円錐部出血をきたした1例
- 垂直性共同視麻痺を呈した両側延髄内側梗塞の1例